Susan M. Blaney

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Yaël P. Mossé, Megan S. Lim, Stephan D. Voss et al. · The Lancet Oncology · 2013 · 701 citations · Full text

Medicine, Oncology, Pediatrics +11

Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy

Tanya Tekautz, Christine Fuller, Susan M. Blaney et al. · Journal of Clinical Oncology · 2005 · 426 citations · Full text

Medicine, Oncology, Pediatrics +17

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

Yaël P. Mossé, Stephan D. Voss, Megan S. Lim et al. · Journal of Clinical Oncology · 2017 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma

Ching‐Hon Pui, Hazem H. Mahmoud, Joseph M. Wiley et al. · Journal of Clinical Oncology · 2001 · 365 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group

Stacey L. Berg, Susan M. Blaney, Meenakshi Devidas et al. · Journal of Clinical Oncology · 2005 · 321 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15